- Home
- CNTB vs CDXS Comparison
CNTB vs CDXS Comparison
Compare CNTB & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | CDXS |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 141.8M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CNTB | CDXS |
|---|---|---|
| Price | $2.59 | $2.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 441.5K | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $64,000.00 | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $0.69 | $0.96 |
| 52 Week High | $3.82 | $3.87 |
Technical Indicators
Market Signals| Indicator | CNTB | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 67.17 |
| Support Level | $2.50 | $2.37 |
| Resistance Level | $2.97 | $2.56 |
| Average True Range (ATR) | 0.27 | 0.19 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 5.00 | 74.54 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.